TakujiHayashl,3ThomasA. Nestor,4CariosRios,5and Alfred G. Scottolini5' We reporta case of lovastatin-induced rhabdomyolysisand resulting life-threatening renal failure. Lovastatin, a hypocholesterolemic agent, decreases endogenous cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (EC 1.1.1.88). This agent has been implicated in causing rare serious side effects in various clinical settings; however, the mechanism of these adverse reactions is not understood. The clinical course of our patient was characterized by profound muscle weakness with marked increases in serum creatine kinase and myoglobin. Light-and electronmicroscopic studies of skeletal muscle of our patient demonstrated a noninflammatory myopathy suggestive of ongoing rhabdomyolysis with vacuolization and focai degeneration of myocytes. The patient's symptoms and the laboratory values referable to rhabdomyolysis resolved after discontinuation of the drug. We speculate that the rhabdomyolysis was due to mitochondrial damage secondary to inadequate synthesis of coenzyme Q and heme A, members of the electron-transport system of the inner mitochondrial membrane. 
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Lovastatin decreases endogenous cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase; EC 1.1.1.88). This enzyme catalyzes an early and major rate-limiting reaction in the biosynthesis of cholesterol. Lovastatin blocks the reduction of HMG-CoA to mevalonate.
As such, lovastatin is efficacious pharmacologically in decreasing the concentration of cholesterol in serum because --66% of total body cholesterol is endogenously produced. However, lovastatin has been implicated in rare serious side effects, including rhabdomyolysis in various clinical settings.
Initial reports
(1, 2) involved organ-transplant recipients who were receiving concomitant cyclosporin therapy. Subsequent reports (3) have cited gemflbrozil, nicotinic acid, and erythromycin as other drugs that enhance lovastatin's rhabdomyolysis-producing potential.
The mechanism by which this adverse reaction is produced is not known. two-day history of shortness of breath and difficulty walking. She had been discharged two weeks earlier from hospitalization for congestive heart failure and, since discharge, had experienced progressive weight gain and pedal edema such that walking had become difficult.
Nine months before this admission, she had suffered an anterior wall myocardial infarct with subsequent echocardiography demonstrating left ventricular dilatation and residual fractionate shortening of 9%. She had a 15-year history of non-insulin-dependent diabetes mellitus but required insulin for euglycemia. She was obese and had a 76-pack-year smoking history. She was diagnosed as hypothyroid at age 11 years.
For 13 days before admission she had been taking lovastatin, 20 mg orally twice a day, for hypercholesterolemia (varying from 8.82 to 9.78 mmol/L). Her medications also included diltiazem, captopril, furosemide, L-thyroxin, and gemuIbrozil for control of serum triglycerides.
She had multiple drug allergies, including allergies to salicylate, penicillin, iodine, and sulfa drugs. On physical examination she was afebrile with a pulse of 102/mm, respiratory rate of 20/mn, and blood pressure of 110/70 mm Hg. There was no skin rash. Scattered rales were noted at the lung bases bilaterally. Heart rate and rhythm were regular with an S3 gallop. There was 2+ pretibial edema. Femoral and popliteal pulses were 2 + bilaterally.
Chest roentgenography revealed cardiomegaly and fluid Symptoms referable to congestive failure resolved over 48 h after diuresis of 8.1 L. However, on the second hospital day, she complained of profound muscle weakness in her lower extremities, which progressed over several hours to include the upper extremities, in addition to pain on palpation so that she could no longer walk spontaneously. Neurological examination revealed intact cranial nerves. Pain and vibration sense were decreased bilaterally in the lower extremities.
Profound muscle weakness was noted proximally, including the biceps, triceps, brachioradialis, iliopsoas, gluteals, hamstrings, and quadriceps femori bilaterally. Interossei, hand grip, gastrocnemii, and anterior tibials showed normal strength bilaterally.
Deep tendon reflexes were 1 + and symmetrical. We speculate that this may be due to inadequate synthesis of CoQ and heme A in the inner mitochondrial membrane with subsequent derangement of cellular energy production and cell death.
